← Back to Search

Local Anesthetic

Hepatic hilar nerve block in ablation patients for Pain Management

Phase 4
Recruiting
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-6 weeks
Awards & highlights

Study Summary

This trial assesses a novel liver nerve block to control pain during tumor control procedures. Initial results suggest it may help. The study will compare it to a sham procedure and assess pain levels over 3 days.

Eligible Conditions
  • Pain Management
  • Liver Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver ablation
Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver chemoembolization
Changes in pain after a hepatic hilar nerve block during and immediately after liver ablation
+1 more
Secondary outcome measures
Changes in anti-nausea medication use after a hepatic hilar nerve block during and immediately after liver ablation
Changes in anti-nausea medication use after a hepatic hilar nerve block during and immediately after liver chemoembolization
Changes in narcotic use after a hepatic hilar nerve block in the early days after liver ablation
+6 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Hepatic hilar nerve block in chemoembolization patientsExperimental Treatment2 Interventions
15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
Group II: Hepatic hilar nerve block in ablation patientsExperimental Treatment2 Interventions
15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
Group III: Placebo procedure in ablation patientsPlacebo Group2 Interventions
15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
Group IV: Placebo procedure in chemoembolization patientsPlacebo Group2 Interventions
15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
446 Previous Clinical Trials
159,646 Total Patients Enrolled

Media Library

Hepatic Hilar Nerve Block Needle placement (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT04769713 — Phase 4
Pain Management Research Study Groups: Hepatic hilar nerve block in ablation patients, Placebo procedure in ablation patients, Hepatic hilar nerve block in chemoembolization patients, Placebo procedure in chemoembolization patients
Pain Management Clinical Trial 2023: Hepatic Hilar Nerve Block Needle placement Highlights & Side Effects. Trial Name: NCT04769713 — Phase 4
Hepatic Hilar Nerve Block Needle placement (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04769713 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much of a hazard does Hepatic hilar nerve block pose to those undergoing ablation?

"The safety of Hepatic hilar nerve block for ablation patients has been evaluated and is deemed acceptable, garnering a score of 3. This Phase 4 trial indicates that this treatment has already gained approval."

Answered by AI

Are individuals being actively solicited to join this research project?

"Clinicaltrials.gov confirms that this experiment, which was originally shared on November 23rd 2021, is still actively seeking participants. The information was last revised on May 31st 2023."

Answered by AI

What maladies is the procedure of hepatic hilar nerve block in ablation patients commonly implemented to counter?

"As a general rule, anesthesia procedures are often managed with hepatic hilar nerve block in ablation patients. Additionally, this technique is also known to be effective for managing labor pain and postoperative ache related to surgical anesthetics."

Answered by AI

How many participants is this research project able to accommodate?

"Affirmative. According to the clinicaltrials.gov listing, this medical experiment is actively recruiting volunteers and was first launched on November 23rd2021 with a most recent update made on May 31st 2023. The study needs 80 patients from 1 hospital or research facility for completion."

Answered by AI

What additional research has been conducted utilizing Hepatic hilar nerve block for pain abatement?

"Currently, 59 clinical trials are underway that focus on the efficacy of Hepatic hilar nerve block in ablation patients. Of those studies, 13 have advanced to Phase 3 testing. The majority of these medical projects are centered around Jefferson, Louisiana; though there is a broad range of 77 sites conducting research related to this intervention."

Answered by AI

What is the objective of this medical experiment?

"This clinical trial will measure the impact of a hepatic hilar nerve block on narcotic use over a 24-hour period. Secondary objectives include evaluating differences in disease response and recording any complications from performing the procedure, as well as changes to anti-nausea medication consumption post-intervention for both groups receiving the treatment or placebo. The RECIST criteria scoring system is being used to compare treatment responses on CT/MRIs 4–6 weeks after liver tumoral chemoembolization, while complication grading uses standards set by the Society of Interventional Radiology rating scale."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures
Louis-martin Boucher 2021. "Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04769713.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top